Included in the formulation
АТХ:G.03.X.C Selective modulators of estrogen receptors
Pharmacodynamics:Selective modulator of estrogen receptors, selectively affects the cells of the mammary gland with pathologically active proliferation, causing their death. Modulates the cytochrome system in such a way that the resulting isoform of cytochrome P450 - CYP1A1 hydroxylates estrogens in the 2-position, with the formation of 2-hydroxyestrone (2-ONE1). The resulting metabolite is an antagonist of the estrogen receptor and blocks its activation by estrogen itself, as well as their dangerous metabolites, in particular 16-α-hydroxyestrone (16α-ONE1). Suppresses induction of estrogen-dependent genes, blocks cytokine mechanisms that stimulate abnormal growth of breast cells. Has antiestrogenic and antiproliferative effect.
Pharmacokinetics:Not studied.
Indications:It is used for the treatment of cyclic mastopathy (mastodynia).
XIV.N60-N64.N64.4 Mammalgia
Contraindications:Individual intolerance, children under 18 years.
Carefully:Hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, 200 mg 2 times a day. Duration of treatment is 6 months.
The highest daily dose: 400 mg.
The highest single dose: 200 mg.
Side effects:Hemopoietic system: eosinophilia.
Digestive system: pain in epigastrium, rarely - weight loss.
Reproductive system: lengthening or shortening of the menstrual cycle.
Allergic reactions.
Overdose:Nausea, vomiting, diarrhea.
Treatment is symptomatic.
Interaction:Strengthens the effects of drugs that metabolize isozymes of cytochrome P450: glucocorticosteroids, indirect anticoagulants, antiepileptic, antiarrhythmic, oral hypoglycemic agents, sex hormone drugs and digitalis.
Special instructions:Does not affect the speed of reactions when driving vehicles and working with moving mechanisms.